Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Virus-based gene therapy research, Cancer Mechanisms and Therapy, CAR-T cell therapy research, and Cancer Research and Treatments.
TATA-box binding protein-associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
Novel fusion superkine, <i>IL-24S/IL-15</i>, enhances immunotherapy of brain cancer.
Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S1 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S5 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S4 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S2 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S8 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S3 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S6 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S7 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing.
CellNeighborEX: deciphering neighbor-dependent gene expression from spatial transcriptomics data.
Neighbor-specific gene expression revealed from physically interacting cells during mouse embryonic development.
MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis
Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis.
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity.
Supplementary Fig. S7 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S5 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S2 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S1 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S3 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S8 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S6 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S4 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S6 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S1 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis